ClinicalTrials.gg
RecruitingNCT07008118Updated Aug 6, 2026

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

A Phase 1 interventional study of INCA035784 in Myeloproliferative Neoplasms, sponsored by Incyte Corporation. Recruiting at 26 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 25 studies in Myeloproliferative Disorders by Incyte Corporation — 3 open to participants now, 7 under way, none of them phase 3. Myeloproliferative Disorders · Incyte Corporation.

Planned enrollment
10th of 23
120 · median 97
Started
2025
the only one that year
Phase 1
6 of 25
3 open now
Registered
24th of 25
by date

Among the 25 studies in Myeloproliferative Disorders by Incyte Corporation, this one is the 10th largest by planned enrollment of the 23 interventional ones that give a count, is the only one that started in 2025, is one of 6 in phase 1, and was the 24th registered.

Myeloproliferative Disorders

668 studies on the registry are indexed under Myeloproliferative Disorders; 111 are open to participants now.

Browse Myeloproliferative Disorders studies →

Open to participants now

3 of the 25 studies in Myeloproliferative Disorders by Incyte Corporation are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 87 Myeloproliferative Disorders studies recruiting now, 63 (72%) set no upper age limit and 18 (21%) stop at 75 or younger; 22 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Myeloproliferative Disorders by Incyte Corporation, or all of them as a file.
02

Study summary

This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.

03

Conditions studied

  • Myeloproliferative Neoplasms

Keywords

  • Myeloproliferative Neoplasms
  • Myelofibrosis
  • Essential thrombocythemia
  • CALR mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older at the time of signing the ICF
  • performance status of 0 to 1 for the dose escalation (Part 1a) and 0 to 2 for the dose expansion (Part 1b)
  • Documented CALR exon-9 mutation
  • Confirmed diagnosis of MPN according to the 2022 ICC criteria:

    • DIPSS+ intermediate-2/high-risk MF with prior JAKi, \<20% blasts, and measurable spleen
    • High-risk ET with >450×10⁹/L
  • Resistant, , intolerant, or has lost response to ≥1 for MF and ≥2 prior lines for ET (unless only a single standard-of-care option is approved in the participating country)
  • No prior stem cell transplant and none planned within 6 months
  • Minimum Laboratory Requirements:

    • Platelet count ≥50 × 10⁹/L
    • ≥1 × 10⁹/L
    • (INR) and activated partial thromboplastin time (aPTT) ≤1.5 × (ULN), unless receiving vitamin K antagonists
    • (ALT) and aspartate aminotransferase (AST) \<2.5 × ULN
    • Total \<2 × ULN
    • Estimated >45 or >30 mL/min (depending on study part)

Exclusion criteria

Exclusion Criteria:

  • Major bleeding or thrombosis (e.g., stroke, DVT, PE) within the past 3 months
  • Active or high-risk , , or infection, or other chronic active infections requiring systemic treatment
  • Active invasive cancer within the past 2 years, except certain early-stage or low-risk cancers (e.g., resected skin, cervical, thyroid, or prostate cancer)
  • Pregnant or unwilling to avoid pregnancy or fathering a child during the study and for a defined period after the last dose.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Part 1a: Dose escalation

    INCA035784 will be administered at a protocol defined starting regimen in 28-day cycles as monotherapy to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\[s\]). Participants with myeloproliferative neoplasm (MPN) will enroll in this group.

    Drug: INCA035784

  • Experimental
    Part 1b: Dose expansion

    INCA035784 will be administered as monotherapy at the RDE(s) identified during Part 1a. Participants with myeloproliferative neoplasm (MPN) will enroll in this group.

    Drug: INCA035784

Interventions

  • DrugINCA035784

    INCA035784 will be administered at the assigned dose in the dose escalation part and at the protocol defined dose in the dose expansion part.

06

What researchers measure

Primary outcomes

  1. Number of participants with Dose Limiting Toxicities (DLTs)

    Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol.

    Time frame: Up to 28 days

  2. Number of participants with Treatment-emergent Adverse Events (TEAEs)

    Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug up to 90 days after the last dose of study drug.

    Time frame: Up to approximately 2 years and 90 days

  3. Number of participants with TEAEs leading to treatment interruption, discontinuation, or delay

    Number of participants with TEAEs leading to treatment interruption, discontinuation, or delay.

    Time frame: Up to approximately 2 years and 90 days

Secondary outcomes

  1. Number of participants with TEAEs leading to dose modification or discontinuation

    Number of participants with TEAEs leading to dose modification or discontinuation.

    Time frame: Up to approximately 2 years and 90 days

  2. Participants with MF: Response using the revised International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) response criteria for myelofibrosis (MF)

    Defined as the percentage of participants with Response using the revised IWG-MRT and ELN response criteria.

    Time frame: Up to approximately 2 years and 90 days

  3. Participants with essential thrombocythemia (ET): Response using the revised IWG-MRT and ELN response criteria for ET

    Defined as the percentage of participants with Response using the revised IWG-MRT and ELN response criteria.

    Time frame: Up to approximately 2 years and 90 days

  4. Participants with symptomatic anemia: Anemia response

    Anemia response as defined in the protocol.

    Time frame: Up to approximately 2 years and 90 days

  5. Participants with spleen volume (SV) ≥ 450 mL at baseline: Percentage of participants achieving spleen volume reduction of ≥ 35% (SVR35)

    Defined as percentage of participants with a protocol defined Spleen Volume Reduction of ≥ 35% (SVR35).

    Time frame: Week 12 and Week 24

  6. Participants with SV ≥ 450 mL at baseline: Percentage of participants achieving spleen volume reduction of ≥ 25% (SVR25)

    Defined as percentage of participants with a protocol defined Spleen Volume Reduction of ≥ 25% (SVR25).

    Time frame: Week 12 and Week 24

  7. Percentage of participants achieving ≥ 50% reduction from baseline of total symptom score (TSS)

    Defined as the percentage of participants achieving ≥ 50% reduction from baseline of TSS.

    Time frame: Week 12 and Week 24

  8. Mean change from baseline in TSS

    Mean change of TSS from baseline.

    Time frame: Week 12 and Week 24

  9. Pharmacokinetics Parameter (PK): Cmax of INCA035784

    Defined as maximum observed plasma concentration of INCA035784.

    Time frame: Up to approximately 2 years and 90 days

  10. Pharmacokinetics Parameter: Tmax of INCA035784

    Defined as the time to reach the maximum plasma concentration of INCA035784.

    Time frame: Up to approximately 2 years and 90 days

  11. Pharmacokinetics Parameter: Cmin of INCA035784

    Defined as the minimum observed plasma concentration of INCA035784.

    Time frame: Up to approximately 2 years and 90 days

  12. Pharmacokinetics Parameter: AUC(0-t) of INCA035784

    Defined as the area under the concentration-time curve up to the last measurable concentration of INCA035784.

    Time frame: Up to approximately 2 years and 90 days

  13. Pharmacokinetics Parameter: AUC 0-∞ of INCA035784

    Defined as the area under the concentration-time curve from 0 to infinity of INCA035784.

    Time frame: Up to approximately 2 years and 90 days

  14. Pharmacokinetics Parameter: CL of INCA035784

    Defined as the apparent oral dose clearance of INCA035784.

    Time frame: Up to approximately 2 years and 90 days

  15. Pharmacokinetics Parameter: Vz of INCA035784

    Defined as the apparent oral dose volume of distribution of INCA035784.

    Time frame: Up to approximately 2 years and 90 days

  16. Pharmacokinetics Parameter: t1/2 of INCA035784

    Defined as the apparent terminal phase disposition half-life of INCA035784.

    Time frame: Up to approximately 2 years and 90 days

07

Study locations

16 of 26 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2028, 29 months after the start.

Of 40 phase 1 interventional studies under Myeloproliferative Disorders, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 140. This study's planned 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2025
First posted
Jun 6, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Mar 14, 2028
CompletionEst.
Dec 14, 2029
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07008118
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Jun 6, 2025
Start date
Oct 1, 2025
Primary completion
Mar 14, 2028 (estimated)
Completion
Dec 14, 2029 (estimated)
Last update
Aug 6, 2026

Study contacts

Incyte Corporation Call Center (US)
Contact
medinfo@incyte.com
1.855.463.3463
Incyte Corporation Call Center (ex-US)
Contact
eumedinfo@incyte.com
+800 00027423
Incyte Medical Monitor
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion